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ImmunoregulationThe term regulatory B cells (B regs) is ascribed to a heterogeneous population of B cells with the
function of suppressing inflammatory responses. They have been described mainly during the last
decade in the context of different immune-mediated diseases. Most of the work on B regs has been
focused on IL-10-producing B cells. However, B cells can exert regulatory functions independently of
IL-10 production. Here we discuss the phenotypes, development and effector mechanisms of B regs
and advances in their role in autoimmunity, infections and cancer.
 2015 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
B lymphocytes are the only cell type in the organism capable of
producing antibodies (Abs). In addition, this population can influ-
ence immunity in multiple ways such as antigen presentation to
T cells, expression of surface co-stimulatory/inhibitory molecules
and cytokine secretion. Consequently, B cells can act as drivers of
innate and adaptive immunity. The name of regulatory B cells (B
regs) is ascribed to a heterogeneous population of B cells with
the function of suppressing directly or indirectly inflammatory
responses. They have been described mainly during the last decade
in the context of different autoimmune and infectious diseases,
and cancer.
2. Regulatory B cells: phenotypes and suppression mechanisms
Many efforts have been made to associate a particular B cell
phenotype to the regulatory function. The term ‘‘regulatory” B cell
to designate a B cell with inhibitory properties was used for the
first time by Mizoguchi and Bhan [1]. Initially, B cells with recog-
nized regulatory functions were the IL-10-producing B cells
described in the autoimmune models of colitis, experimentalautoimmune encephalitis (EAE) and arthritis [2–4]. These cells
can present different phenotypes in mice. Several subsets of IL-
10-producing B regs show expression of CD1d, such as CD1dhi-
CD5-B220lowCD11b+IgM+ [2], CD1dhiCD5+ (denominated B10 cells)
[5] and CD1dhiTim+CD5+ [6], which were linked with the protection
from autoimmune diseases. However, it is important to point out
that CD1d is expressed on a wide variety of cell types. Indeed, it
is constitutively expressed in most B cells (not only those secreting
IL-10), with the highest expression on MZ B cells (CD21hiIgMhi-
IgDlCD24intCD23CD43) and T2 B cells (CD21hiIgMhiIgDhiCD23+)
[7]. Peritoneal CD5+B1 cells have been described as the main
source of B cell-derived IL-10 [8]; however, these cells were asso-
ciated more to autoimmunity promotion than to immunoregula-
tion [9]. In addition, it has been demonstrated that CD5+ B cells
synthesize as much IL-10 as CD5neg B cells after mitogen- or
antigen-stimulation, indicating that B cells produce IL-10 indepen-
dently of CD5 expression [10].
Although little is known about human B regs, it has been
reported that B cells from healthy individuals and patients with
active Rheumatoid Arthritis (RA) presenting a phenotype
CD19+CD24hiCD38hiCD1d+ were able to suppress the release of
IFN-c by CD4+T cells but did not suppress IL-6 and IL-8 production
[11]. In addition, a subset of IL-10-producing CD24hiCD27+ B cells
analogous to murine B10 cells was also shown to exist in humans
[12]. There are also descriptions of human IL-10 and TGF-b
producing-CD25hiCD27hiCD86hiCD1dhi B cells able to suppress
autologous T cell proliferation and to induce the generation of
Foxp3+CTLA4+ regulatory T cells (Tregs) in a cell-to-cell
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Griffin and Rothstein reported the capacity of CD11b+ B1 cells, a
recently described subpopulation of B1 cells [14], to spontaneously
produce IL-10 and suppress T-cell activation [15]. Owing to their
capacity to either stimulate T-cell proliferation [14] or suppress
T-cell activation [15], these B cells should be able to guide the
immune response.
Taking into account that IL-10-producing B cells express differ-
ent surface markers, it is not possible to assign the regulatory func-
tion to a unique phenotype, and it is probable that surface
phenotypes are more related to the origin of the B cell subset
rather than to their function. In addition, detection of intracellular
cytokines involves stimulation, fixation and permeabilization,
which is likely to alter the initial phenotype of B cells, hindering
the correct phenotypification of the B cell subset in study.
As a result of the impossibility to define a particular phenotype
for the B reg cell subset, one of the main challenges of B reg cell
research is the identification of a B reg cell-specific transcription
factor analogous to Foxp3 in Tregs [16], as it has been previously
proposed [17]. The identification of such molecule would allow
the direct association of the regulatory function to a transcription
factor instead of to a surface phenotype or functional assay. This
may accelerate B reg identification in different diseases as well
as the design of therapeutic trials for B reg induction and tolerance
restoration.
As we mentioned, B regs may regulate different scenarios
through the expression of cytokines other than IL-10, including
TGF-b, IL-35, and IL-17. Through TGF-b production, lipopolysaccha-
ride (LPS)-activated B cells can induce apoptosis of CD4+ [18] and
anergy in CD8+ [19] effector T cells. TGF-b is produced by both
CD5+ and CD5- B cells from autoimmune-prone NZB mice [20]
and it is also expressed by normal human B cells [21]. These
TGF-b+ B cells play essential roles in the induction of tolerance to
non-IgE mediated food allergy in atopic dermatitis [21]. IL-35-
producing B cells were identified as key players in the negative reg-
ulation of immunity as mice in which only B cells did not express
IL-35 failed to recover from the T-cell-mediated demyelinating
autoimmune disease EAE [22]. We reported that B cells were the
main splenic population producing IL-17 during Trypanosoma cruzi
infection. Furthermore and in agreement with the regulatory role
of IL-17 during this parasite infection [23], transfer of WT B cells
but not of IL-17-deficient B cells decreased the inflammatory
response and mortality of T. cruzi infected B cell-deficient mice
[24]. These results highlight that IL-17+ B cells play critical roles
in the regulation of inflammation.
It was of great interest to find that within the cytokine-
producing B regs described in infections by Shen et al. [22] and
our group (Bermejo et al. [24]), there was an important proportion
of CD138+ plasma cells. In 2012, Maseda et al. [25] first suggested
that splenic Pax5+ B10 cells could rapidly convert into plas-
mablasts after in vivo or in vitro activation; nevertheless, they
did not test the regulatory capacity of the arising plasmablasts/-
plasma cells. Furthermore, during the characterization of B cells
with potential regulatory function generated in the draining lymph
node during EAE, IL-10-producing plasmablasts with a mixed phe-
notype in terms of IgM and IgG expression and a reasonable degree
of class switching were detected [26]. However, it is not clear
which plasmablast population, whether the IgM+ or the IgG+, is
expressing more IL-10. The generation of these regulatory plas-
mablasts was dependent on Blimp-1 and IRF-4 as mice lacking
plasmablasts by genetic ablation of the transcription factors
Blimp-1 or IRF-4 in B lineage cells developed an exacerbated EAE.
In contrast, disruption of Bcl-6, a transcription factor that controls
B cell germinal center formation, did not reduce CD138+CD44hi
plasmablast numbers and did not exacerbate EAE development,
suggesting that regulatory plasmablast generation was mainly inextrafollicular foci and not dependent on germinal center
responses [26]. Accordingly, we observed that IL-17-producing
plasmablasts and plasma cells with high expression of IgM are
located outside the splenic follicles and proximal to the central
arteriole (T cell zone) [24], possibly as product of the strong
extrafollicular plasmablast response produced in T. cruzi infection
[27]. Therefore, as suggested by Mauri and Blair [28], it seems plau-
sible to hypothesize that regulatory plasmablasts are contained
within the IgM+ plasmablast pool, and are probably short-lived
plasma cells. It would be of great interest to further examine in
these regulatory plasmablast populations their degree of somatic
hypermutation, their ability to simultaneously release cytokines
and antibodies, their expression of inhibitory receptors and how
long these cells can persist after the resolution of inflammation.
Finally, there is evidence that B cells would regulate immunity
not only through cytokine production but also via surface mole-
cules, such as CD39, CD73 and Programmed death-ligand 1 (PD-
L1). Indeed, a novel population of B cells has been shown to regu-
late colitis in an IL-10-independent manner but dependent on the
expression of CD39 and CD73 [29]. CD39 is an ectonucleoside
triphosphate diphosphohydrolase-1 and CD73 is an ecto-50-
nucleotidase which hydrolyze exogenous adenosine triphosphate
(ATP) to adenosine 50-monophosphate (AMP) and finally produce
immunosuppressive adenosine (ADO) [30–32]. In the dextran sul-
fate sodium salt-induced colitis murine model, transfer of ADO-
producing CD73+ B1 cells conferred resistance to the colitis suscep-
tible CD73/ mice [29]. In addition, experiments performed by
Saze and collaborators [33] demonstrated that upon activation,
human B cells increase their expression of CD39 and acquire the
capability to downregulate proliferation of autologous CD4+ or
CD8+ T cells. They also showed that 50-AMP and perhaps other
components of the ADO pathway (such as inosine and hypoxan-
thine) produced by activated B cells are potentially responsible
for this inhibitory activity. ADO not only suppresses T cell but also
B cell proliferation since 2-chloroadenosine, used instead of ADO
because of its greater stability, inhibited B cell proliferation. The
result suggests an immunosuppressive autocrine mechanism
mediated by the CD39/ADO pathway [33].
As regards the role of PD-L1-expresing B cells there are a few
reports. Like in PD-L1+ Tregs which can transduce an inhibitory sig-
nal into effector T cells through interacting with programmed
death-1 (PD-1), PD-L1-expressing B cells also have been proved
to exert a suppressive role on PD1-expressing CD8+ T cells, inhibit-
ing their proliferation and effector functions in Salmonella infection
[34] and cancer [35]. Considering the great impact of PD-1/PD-L1
pathway on cancer and viral infection progression [36–38], more
studies about PD-L1-expressing B cells or their products of differ-
entiation are needed.3. Induction and development of regulatory B cells
The diversity in the phenotypes reported for B regs has led to
controversies about their origin and development. Regarding B10
development, several reports suggest that B10 cells are T cell-
independent. Indeed, major histocompatibility complex (MHC)
class I and class II molecules, and CD1d expression are not required
for B10 cell development [39]. Furthermore, naïve B cells produced
large amounts of IL-10 upon activation with TLR-2, -4, or -9 ligands
in vitro, but not upon stimulation via CD40 or B cell-receptor for
antigen (BCR) either alone or combined [40]. The idea that intrinsic
TLR signaling induces suppressive B cells was confirmed in vivo in
a model of EAE. Mice in which only B cells lacked TLR-2, TLR-4 or
the major TLR-signaling adaptor, MyD88, developed a chronic form
of the disease, whereas mice with wild-type B cells recovered after
a short episode of paralysis [40]. Thus, the suppressive functions of
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directly by the signals that stimulate immunity [41]. In addition,
TLR-signaling may be important not only for B10 development
but also for TGF-b producing B cells that emerge after stimulation
with LPS [18].
Contrary to results reported in vitro, BCR signaling may also be
an important stimulus for B10 development in vivo. It has been
reported that transgenic mice with a fixed BCR have a decrease
of approximately 90% in the frequency of B10 cells [39], and mice
deficient/transgenic for receptors that influence BCR signaling
showed altered numbers of B10 [5]. For instance, a deficiency in
CD19, a molecule that promotes BCR signaling, resulted in a
decreased B10 development whereas overexpression of CD19 in
mice expressing transgenic human-CD19 caused an increase in
B10 numbers [5]. In a similar manner, deficiency in CD22, a nega-
tive regulator in BCR signaling, boosts the numbers of B10 [42]
[43]. Then, this may be an antigen-specific mediated induction of
B10 in vivo since, as we have previously mentioned, Fab2 anti-
IgM Ab did not induce IL-10 expression [39].
Unexpectedly, B cell-activating factor (BAFF), a member of TNF
family cytokines that is a key regulator for B cell maturation and
function and whose increase is associated to autoimmunity [44],
induced IL-10 production by B cells mainly derived from marginal
zone (MZ). Notably, BAFF treatment in vivo increased the number
of IL-10-producing B cells in marginal zone regions, and the trans-
fer of BAFF-induced CD5+CD1dhi IL-10-producing B cells partially
prevented the development of collagen-induced arthritis (CIA)
[45].
On the other hand, an interaction between B10 cells and T cells
has also been described. This interaction may be necessary to
explain how IL-10 production by B10 cells and the negative regu-
lation of antigen-specific autoimmune inflammation occur
in vivo, without inducing systemic immunosuppression. Using a
mouse model for multiple sclerosis, Yoshizaki and collaborators
[46] demonstrated that B10 cell maturation into functional
IL-10-secreting effector cells in vivo requires IL-21 and
CD40-dependent cognate interactions with T cells. Moreover,Fig. 1. Detection and characteristic of B regs in different infections. Different microorga
profiles that control microorganism-induced inflammation.ex vivo stimulation of B cells via CD40 and IL-21 receptor favored
B10 cell development and expansion, and the generated IL-10-
producing B10 effector cells could inhibit disease symptoms once
the autoimmune disease was established. Then, these data may
indicate that while B10 cells do not require exclusively T cells to
acquire IL-10 competence, they do need cognate interactions with
IL-21-producing T cells to become functional regulatory IL-10+ B
cells in vivo.
Concerning the origin of B regs beyond B10 cells, it has been
reported that TIM-1 (T cell Ig domain and mucin domain protein
1) expressing regulatory B cells can be induced through TIM-1 liga-
tion [6]. TIM-1 is a co-stimulatory molecule that regulates immune
responses by modulating CD4+ T cell effector differentiation. Roth-
stein’s group showed, in a transplant murine model in vivo [6], that
B cells rather than T cells, and in particular IL10-producing among
all B cell populations, expressed TIM-1. TIM-1+ B cells, that
included transitional, MZ and follicular B cells as well as the B cell
population characterized as CD1dhiCD5+, express not only IL-10 but
also IL-4, promote Th2 responses, and are able to transfer allograft
tolerance. In conclusion, this work proposes TIM-1 as a novel ther-
apeutic target for modulating the immune response and provides
insight into the signals involved in the generation and induction
of B regs.
Another population of B regs induced in T cell-independent
manner is the IL-17-producing B cells. Its program operates inde-
pendently of key candidate receptors on the B cell surface, such
as BCR, CD40, and MyD88-dependent innate receptors. Further-
more, this process is also independent of IL-6, IL-23, AhR, RORct,
and RORa [24], which are usual signals required for IL-17 produc-
tion by T cells or innate lymphoid cells [47–51]. B cell expression of
IL-17 can be induced directly in vitro by live T. cruzi trypomastig-
otes. We found that the parasite-derived trans-sialidase was
responsible for B cell activation and IL-17 production via a mecha-
nism that modifies the glycosylation of B cell surface molecules
[24]. Our observations suggest that the generation of IL-17+ B cells
may be an unappreciated feature of the B cell innate immune
response to T. cruzi infection that may condition the further T cellnisms (parasites and bacteria) induce B regs with different phenotype and cytokine
Table 1
Stimuli reported to induce B regs in vivo and in vitro.
Stimuli Type of B regs induced
TLR-2, 4 and 9 ligands B10 [40]
LPS TGF-b-producing B cells [18]
BCR signaling in vivo B10 [39,42,43]
BAFF IL-10-producing MZ B cells [45]
CD40 and IL-21 receptor stimulation B10 [46]
TIM-1 ligation IL-10- and IL-4-producing B cells [6]
Trypanosoma cruzi trans-sialidase IL-17-producing B cells [24]
IL-1b and IL-6 IL-10-producing B regs [53]
IL-33 IL-10-producing B regs [54]
IL-35 IL-35- and IL-10-producing B regs [55]
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cytokine-producing plasma cells, although in this case the cytoki-
nes produced are IL-10 and IL-35 [22,52]. Therefore, it can be
inferred that, in several infectious diseases and in response to the
direct effect of microbial-derived compounds, T cell independent-
B cell responses are able to adopt biologically relevant
Ab-independent functions.
B regs can also emerge in inflammatory microenvironments via
cytokine stimulation. Recently, it has been demonstrated that a B
reg cell population arose in response to the pro-inflammatory
cytokines IL-1b and IL-6, which are produced after the induction
of antigen-induced arthritis [53]. Moreover, B regs also appeared
in response to IL-33 (a recently identified IL-1 family member) pro-
tecting mice from inflammatory bowel disease [54]. Finally, a novel
B reg subset (i35Breg) was induced by IL-35. This i35 B regs can
also produce IL-35, orchestrating a positive feedback loop that
increases the amounts of B regs [55].
In summary, the available information (summarized in Table 1)
indicates that B regs emerge in response to the same inflammatory
signals that drive the immune system activation, and can limit the
developing inflammation avoiding an exacerbated response.
Accordingly, and based on the idea that B regs are not lineage
specific, Rosser and Mauri [17] suggested that B regs are short-
lived effector cells that are expanded in response to inflammation
or, alternatively, that B regs are an inflammation-inducible subset
that enters in a further differentiation pathway after the resolution
of an inflammatory response, such as the maturation of immature
B cells into plasmablasts.
However, it may also be conceivable that B regs are a particular/
specialized B cell subset expressing a particular transcription factor
that is amplified in response to different inflammatory stimuli or
specific-antigens and acquires different phenotypes, including dif-
ferent sets of effector regulatory molecules, depending on the char-
acteristics of the inducing stimuli.
4. Regulatory B cells in autoimmunity
B10 cells and their IL-10-dependent regulatory function have
been extensively described in the autoimmune model of EAE.
How B or B10 cells contribute to the initiation, development or reg-
ulation of this disease has been studied by Matsushita and collab-
orators [56]. Their report showed that CD20-mediated B cell
depletion exacerbated the disease symptoms if performed before
the induction of EAE due to the depletion of the B10 cell popula-
tion. However, if the depletion was performed during EAE progres-
sion, the disease symptoms were suppressed, mainly because B
cells promoted the generation of pathogenic antigen-specific
CD4+ T cells and their influx into the Central Nervous system
[56]. This report provided insights about how important it would
be to consider the timing of the autoimmune disease and the roles
of the different B cell populations when establishing therapeutictreatments involving depletion or an autologous adoptive transfer-
ence. Furthermore, PD-L1+IL-10+ B cells were shown to be the key
players in estrogen (E2)-mediated protection against EAE [57–59].
E2 has been proved to protect mice from EAE, while this protection
was abrogated in B cell-deficient (muMT) mice [60]. E2 treatment
upregulated the expression of PD-L1 on B cells and increased the
numbers of IL-10-producing CD1dhiCD5+ B cells [60]. In addition,
E2 treatment in PD-L1/ mice was also ineffective, and transfer
of PD-L1/ B cells to muMT mice could not restore the protection
observed in WT mice [57]. In particular, in PD-L1/ mice, a
decrease in the percentage of CD1dhiCD5+ B cells was observed
together with a decrease in splenocyte production of IL-10 [57].
When IL-10-producing B cells (PD-L1+) were transferred into
muMT [59] or PD-L1/ [58] mice, there was a partial recovery of
the E2-mediated protection mechanism. In a different model of
EAE, regulatory B cells were demonstrated to exert their suppres-
sive function also through PD-L1 [61]. PD-L1hi B cell-transfer
before EAE induction delayed the onset and ameliorated the dis-
ease symptoms. This correlated with a decrease in CD4+ T follicular
helper (Tfh) cell percentages and numbers as well as in Central
Nervous system infiltration, together with a decrease in myelin
oligodendrocyte glycoprotein (p35–55) (MOG35–55)-specific IgG,
IFN-c and IL-17. Tfh regulation may be independent of IL-10 since
PD-L1hi B cells do not quite produce this cytokine and transfer of
PD-L1hiIL-10/ B cells suppressed Tfh proportion and numbers
when immunized with KLH. Recipients receiving PD-L1hi B cells
showed a downregulation of the proportion and number of T-
bet+, Gata3+ and RORct+ CD4+ T cells [61].
Studies suggested that B regs have also protective effects in dif-
ferent spontaneous models of lupus. For instance, adoptive transfer
of splenic CD1dhiCD5+ B cells from wild type NZB/W mice prolongs
survival of the highly susceptible CD19/ NZB/W recipients [62].
Moreover, in a MRL/lpr mice model, transfer of unmanipulated
T2 B cells isolated frommice with established lupus failed to confer
protection, whereas transfer of in vitro anti-CD40-activated T2 B
cells control the progression of lupus and survival through an IL-
10-dependent mechanism. B cells isolated from donor MRL/lpr
mice stimulated with anti-CD40 converted autologous effector T
cells into regulatory IL-10-producing T cells. Interestingly, in vivo
administration of agonistic anti-CD40 mAb in MRL/lpr mice pro-
moted the generation of B regs and delayed the progression of
the lupus-like disease [63]. A study with systemic lupus erythe-
matosus (SLE) patients suggested that their B regs had a significant
impairment in their ability to regulate T-cell cytokine responses.
CD19+CD24hiCD38hi B cells isolated from SLE patients, but not
healthy patients, failed to produce IL-10 in response to CD40 stim-
ulation, and were unable to inhibit Th1 responses [64].
Suppressive functions for IL-10-producing B cells were reported
for alternative autoimmune models. For instance, chimeric mice
with an IL-10 deficiency in B cells presented an increase in IFN-
c- and IL-17-producing CD4+ T cells, and a decrease in IL-10-
producing CD4+ T cells during a model of CIA which correlated with
an exacerbated clinical score [65]. In addition, BAFF-induced IL-10-
producing B regs also protected mice from this autoimmune dis-
ease [45]. Furthermore, IL-33-induced IL-10-producing B regs pre-
vented upon transfer the development of spontaneous colitis in IL-
10KO mice [54]. Last year Wang and collaborators [55] described
the IL-35-dependent induction of IL-35- and IL-10-producing B
regs which were capable of conferring protection against murine
uveitis through inhibition of the Th17/Th1 response and the expan-
sion of T regs. Notably, these B regs could also be induced ex-vivo
from human B cells [55], providing new prospects for autologous
adoptive B cell therapies.
Accordingly, regarding B regs as a therapeutic strategy for
autoimmunity, it has been shown that treatment of arthritis
patients with Tocilizumab (an anti-IL-6R antibody with antagonis-
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the promotion of their regulatory function. After treatment, the
shift in B cell properties lied in an increase of TGF-b expression
in the CD25hi B cells, and a reduction in the B cell activation status
(evaluated through CD69 and MHC-II expression), suggesting that
the induction/expansion of B regs may be one of the mechanisms
by which anti-IL-6R may produce beneficial effects in rheumatoid
arthritis [66]. The precise mechanism by which a dissociation of IL-
6/IL-6R complex and/or the neutralization of IL-6 signaling could
possibly lead to the expansion of B cells with regulatory character-
istics requires better understanding. Another report demonstrated
that Laquinimod, an experimental immune modulator for multiple
sclerosis, was able to expand IL-10- and TGF-b-producing B and T
cells [67].
5. Regulatory B cells in infections
Helminths are the most remarkable pathogens for their ability
to down-regulate host immunity to protect themselves from elim-
ination, minimizing immune-inflammatory disorders in the host.
Ten years ago, the Th1–Th2 dichotomy was invoked to explain
the regulation of immunopathologic diseases. Thus, reduced Th1
associated autoimmune pathologies were observed following
Th2-inducing helminth infections [68–70]. Later, it was also shown
that during these type of infections, the T reg population is
expanded and that transfer of the parasite-induced CD4+CD25+ T
regs suppressed inflammation following airway allergen challenge
[71]. Interestingly, B regs are also expanded in the context of hel-
minth infections and exert regulation in different inflammatory
models in mice [72–75] as well as in humans [76]. B cells from
Heligmosomoides polygyrus infected, but not naïve, mice are able
to transfer a downmodulatory effect on allergy, significantly sup-
pressing airway eosinophilia, IL-5 secretion and pathology follow-
ing allergen challenge (See Fig. 1). The same cell population can
also alleviate autoimmune-mediated inflammatory events in the
Central Nervous system when transferred to uninfected mice
undergoing MOG35–55-induced EAE. In both allergic and autoim-
mune models, reduction of disease was achieved with B cells from
helminth-infected IL-10-deficient donors, indicating that the sup-
pression mechanism was independent of IL-10, and the phenotype
of these B cells suggested that they were follicular B regs [77].
Schistosomes can also induce functional B regs in humans that
may contribute to the regulatory microenvironment found in
schistosomiasis. Compared with uninfected donors, a greater per-
centage of B cells from Schistosoma haematobium-infected donors
expressed cytoplasmic IL-10 and membrane-bound latency-
associated peptide/TGF-b1. T cells produced less IFN-c, IL-4, and
IL-17 when co-cultured with B cells from Schistosome-infected
individuals, and their conversion to CD25hiFoxp3+ and their per-
centage of IL-10+ T cells were enhanced. Interestingly, depletion
of the CD1dhi IL-10-producing B cell subset resulted in less IL-10+
T cells in the S. haematobium-infected group, with no changes in
the levels of Foxp3+ T regs [78] (See Fig. 1). Notably, B regs may
regulate not only Th1 or Th17 inflammatory responses, but also
Th2-associated pathologies [72,74,77] and cytokines related to a
Th2 profile such as IL-4 [73,78].
Not only helminths but also protozoan parasites can trigger B reg
development. Blood-stage Plasmodiumberghei induced expansionof
IL-10-producing B reg cells in C57BL/6mice. Adoptive transfer of IL-
10+ B regs to P. berghei infectedmice significantly reduced the accu-
mulation of NK and CD8+ T cells and hemorrhage in brain tissue, and
improved the survival of the mice compared with control groups
without altering parasitemia. Treatment of B reg-cell recipientmice
with anti-IL-10 receptor mAb blocked the protective effect of B reg
cells [79]. As B regs can contribute to regulation of inflammationand prevent immunopathology, they may also suppress protective
host responses and increase susceptibility for infections. For
instance, it was reported that muMT mice were more resistant to
Leishmania donovani infection than control WT mice due to the fact
that IL-10 production by MZ B cells suppressed the expression of
Granzime B (GrB) inNK cells and of IFN-c by CD4+ T cells [80]. B cells
stimulated following in vitro or in vivo encounter with Leishmania
major expressed CD1d and CD5 and secreted IL-10 that down-
regulated IL-12 production by L. major-stimulated dendritic cells.
In addition, it was reported that IL-10 produced by regulatory
CD1dhiCD5+ B cells in response to L. major is critical for Th2 cell
development in BALB/c mice [81] (See Fig. 1).
Results from our group have shown the critical role of IL-17+
producing B cells to control the inflammatory response and favor
host resistance during T. cruzi infection [24] (See Fig. 1). The mech-
anisms underlying this protective effect involved, at least in part,
the IL-17-mediated recruitment of IL-10-producing regulatory
neutrophils [23].
Finally, in case of bacterial infection, during Salmonella typhi-
murium infection, MyD88-dependent IL-10 secretion by CD138+ B
cells suppressed neutrophils, NK cells, and inflammatory T cells,
which compose the protective immune response in this infection
[52] (See Fig. 1). Respect to surface inhibitory molecules, PD-L1-
expressing B cells alone or together with PD-L1-expressing mono-
cytes suppressed the expansion of CD8+ OTI cells favoring the per-
sistence of the OVA-carrying-bacteria and Salmonella chronic
infection [34].
6. Regulatory B cells in cancer
Despite the fact that the immunosuppressive function of B regs
could help achieve beneficial effects moderating autoimmune dis-
orders and controlling exacerbated inflammatory responses in
infections, its role in cancer can be deleterious. In this line, B cells
recruited by the chemokine CXCL13 into prostate cancer tumors
promote the progression of castrate-resistant prostate cancer by
producing lymphotoxin, which activates a signaling cascade that
favors prostate cancer survival [82].
In the context of a skin cancer model induced by 7, 12-dimethyl
benz[a]anthracene/terephthalic acid (DMBA/TPA), CD19+ cells are
responsible for producing the pro-inflammatory cytokine TNF, well
recognized as a critical tumor promoter. Besides, TNF/ mice, nor-
mally resistant to this model of chemical induced skin cancer,
become susceptible upon transfer of CD19+ cells from WT DMBA/
TPA treated mice. Hence, Jh (B cell-deficient) and Rag2/ (T and B
cell deficient) mice were partially and totally resistant to papilloma
development, respectively. The protection of tumor growth seen in
TNF/ mice was associated with increased skin levels of IFN-c
and CD8+ T cells and a decrease in macrophages and IL-10-
producing B regs [83].
Horikawa and colleagues demonstrated that B10 cells could neg-
atively affect the phagocytic capacity of macrophages. Adoptively-
transferred B10 cells dramatically suppressed anti-CD20 mAb-
mediated lymphoma depletion by inhibiting mAb-mediated mono-
cyte activation and effector function through IL-10-dependent
mechanisms [84]. Furthermore, B regs have been reported infiltrat-
ing lungmetastases of breast cancerwhose primary role is to induce
TGF-b-dependent conversion of resting CD4+ T cells to Foxp3+ T regs.
These B cells phenotypically resemble activated but poorly prolifer-
ative mature B2 cells (CD19+CD25hiCD69hi) that constitutively
express active Stat3 and B7-H1hiCD81hiCD86hiCD62LloIgMint. In
the absence of B regs, 4T1 tumors cannot metastasize into the lungs
efficiently due to poor T reg conversion [85].
B cells are also able to suppress protective immune responses
against tumors through cytokine-independent mechanisms. IL-21
M. Gorosito Serrán et al. / FEBS Letters 589 (2015) 3362–3369 3367produced by T regs induced a high expression of GrB in human B
cells and an outgrowth of this population, which thereby limited
T-cell proliferation by a GrB-dependent degradation of the T-cell
receptor f-chain [86].
A very elegant work from Shalapour et al. [35] showed that
mouse B cells modulate the response to low-dose oxaliplatin
which promotes tumor-directed CTL activation by inducing
immunogenic cell death. Three different mouse prostate cancer
models were refractory to oxaliplatin unless mice were genetically
or pharmacologically depleted of B cells. In this model, the crucial
immunosuppressive B cells are IgA-expressing plasmocytes that
exert their regulatory function through IL-10 and PD-L1. Elimina-
tion of these cells, which also infiltrate human-therapy-resistant
prostate cancer, allows CTL-dependent eradication of oxaliplatin-
treated tumors [35].
7. Concluding remarks
There is a growing body of evidence that shows that B regs are
key players in different situations where the immune system is
hyperactivated. B regs have been shown to exhibit phenotypes cor-
responding to MZB1 and follicular B cells as well as plasmablasts.
Given their diverse phenotype, it remains unclear whether they
emerge from a particular unique B cell subset, or if every B cell sub-
set could acquire a regulatory function upon stimulation in the
appropriate condition. It also remains unclear if the regulatory
function is exclusive, or if a B reg can also exert other B cell func-
tions like antibody secretion. An unanswered relevant issue is if
there is any surface molecule or transcription factor that is com-
monly and specifically expressed by all B regs.
Altogether, the current literature supports the conclusion that B
regs can regulate distinct profiles of inflammation, including Th1,
Th17, and Th2. Furthermore, despite the fact that the majority of
these regulatory mechanisms involve IL-10 expression, many B
reg-mediated regulatory mechanisms comprise different cytoki-
nes, cell-to-cell contact, and even adenosine. This evidence may
encourage further investigation beyond IL-10 and the well-
known regulatory pathways.
Targeting B regs for immune therapeutic strategies may have
relevant prospects and development of B reg-induction protocols
may be a significant advance in this area. In this regard, reports
showing that infection-induced B regs can ameliorate allergic or
autoimmune diseases provide insights for novel screening induc-
tion protocols and applications for each induced B reg.
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